PARP1 and neoplasm: To understand if this direct reprogramming of macrophages by PARP inhibition contributes to the anti-tumor response elicited by olaparib in vivo, we introduced ex vivo-differentiated macrophages into tumors in vivo (Figures 2E, 2F, S2C, and S2D).